Reactions 1704, p283 - 2 Jun 2018
ALT increased: case report
In a study of seven patients, one patient [age and sex not
stated] was described who developed ALT rise following
treatment with nivolumab and pembrolizumab [routes,
dosgaes, durations of treatments to reaction onset not stated].
The patient, who had cancer [unspecified], received treatment
with nivolumab and pembrolizumab. The patient also had
concurrent HCV infection. Subsequently, the patient
developed rise in ALT level (grade II). Therefore, the patient
received treatment for HCV infection and consequently the
ALT level returned to baseline.
Author comment: "Our results indicate that patients with
metastatic melanoma and NSCLC can be safely treated with
anti-PD1 immunotherapy in the context of HBV/HCV
infection. Only one patient demonstrated an ALT rise greater
than CTCAE Grade 1 severity".
Kothapalli A, et al. Safety and efficacy of anti-PD1 therapy for metastatic
melanoma and non-small cell lung cancer in patients with concurrent viral
hepatitis. Australasian Journal of Dermatology 59 (Suppl. 1): 79, May 2018.
Available from: URL: http://doi.org/10.1111/ajd.17_12815 [abstract] -
Reactions 2 Jun 2018 No. 17040114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved